Two-Step Screening Detects Ovarian Cancer Early

This article originally appeared here.
Share this content:
Two-Step Screening Detects Early-Stage Ovarian Cancer
Two-Step Screening Detects Early-Stage Ovarian Cancer

(HealthDay News) -- A two-step screening process using the Risk of Ovarian Cancer Algorithm (ROCA) followed by transvaginal ultrasound (TVS) for those at high risk, shows high specificity in early detection of ovarian cancer in postmenopausal women, according to a study published online Aug. 26 in Cancer.

Karen H. Lu, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues followed 4,051 postmenopausal women over 11 years using an annual CA125 test and ROCA to triage women to the next annual CA125 test (low risk), a repeat CA125 test at three months (intermediate risk), or TVS and referral to a gynecologic oncologist (high risk).

The researchers found that the annual rates of referral averaged 5.8% for a CA125 test in three months and 0.9% for TVS and review by a gynecologic oncologist. On the basis of TVS, 10 women underwent surgery, and four invasive early-stage ovarian cancers were detected (one stage IA, two stage IC, and one stage IIB) for a positive predictive value of 40%. Specificity for the two-step screening strategy was 99.9%.

"The results from our study are not practice-changing at this time; however, our findings suggest that using a longitudinal (or change over time) screening strategy may be beneficial in postmenopausal women with an average risk of developing ovarian cancer," Lu said in a statement.

Several authors disclosed financial ties to the medical diagnostics industry; one author is a co-inventor of ROCA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs